- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
FDA advisory committee poised to make recommendation regarding CAR T therapy from Novartis that represents the first possibility of treatment calling on the body's own engineered cells to attack cancer.
My three top predictions for the next six months.
The FDA has placed a clinical hold on three combination studies of Merck's Keytruda in multiple myeloma.